


11-12-0

DT06 Rec'd PCT/PTO

08 NOV 2002



**TRANSMITTAL LETTER**  
**(General - Patent Pending)**

Docket No.  
PG3654USw

In Re Application Of:  
ANDERSON, et. al.

Serial No.  
09/937,232

Filing Date  
09/24/2001

Examiner  
CARTAGENA

Group Art Unit  
3754

Title:

VALVE

RECEIVED

FEB 24 2003

TECHNOLOGY CENTER R3700

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is:

**Petition to Commissioner for Reconsideration of Decision on Petition of PCT Legal Office Under 37 C.F.R. 1.181**

**TAB 1: Copy of Transmittal Letter to the DO/EO/US Concerning a Filing Under 35 U.S.C. 371**

**TAB 2: Copy of Combined Declaration for Utility or Design Patent Application with POA**

**TAB 3: Copy of Filing Receipt and Notice of Acceptance**

in the above identified application.

- ☐ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 07-1392 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Signature

Dated:

November 8, 2002

Robert J. Smith  
Registration No.: 40,820  
Telephone: 919-483-9616



23347

PATENT TRADEMARK OFFICE

CC:

I certify that this document and fee is being deposited on \_\_\_\_\_ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

Express Mail No.:  
EV022027699US

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**Applicant(s): **ANDERSON, et. al.**

Docket No.

**PG3654USw**

Serial No.

**09/937,232**

Filing Date

**09/24/2001**


Examiner

**CARTAGENA**

Group Art Unit

**3754**

Invention:

**VALVE****NOV 08 2002****RECEIVED****FEB 24 2003****TECHNOLOGY CENTER R3700**

I hereby certify that this **Petition to Commissioner for Reconsideration of Decision and Corresponding Docs**  
(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  
37 CFR 1.10 in an envelope addressed to: The Commissioner of Patents and Trademarks, Washington, D.C.

20231-0001 on **11/08/2002**  
(Date)

**Ban Younan**

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

**EV022027699US**

("Express Mail" Mailing Label Number)

**Note: Each paper must have its own certificate of mailing.**



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Anderson et al.	)	
	)	
Int'l Appln. No.: PCT/EP00/01444	)	Examiner: Cartagena
	)	
Int'l Filing Date: February 23, 2000	)	
	)	
U.S. Serial No.: 09/937,232	)	Art Unit: 3754
	)	
U.S. Filing Date: September 24, 2001	)	Applicant Docket #: PG3654USw
	)	
Title: VALVE	)	

**PETITION TO COMMISSIONER FOR RECONSIDERATION  
OF DECISION ON PETITION OF PCT LEGAL OFFICE  
UNDER 37 C.F.R. 1.181**

Commissioner for Patents  
Washington D.C. 20231

Sir:

Pursuant to 37 C.F.R. 1.181, this is a Petition to the Commissioner requesting reconsideration of a Notification of the PCT Legal Office issued September 25, 2002 vacating the Notification of Acceptance of Application under 35 U.S.C. 371 and 37 CFR 1.494 or 1.495 (Form PCT/DO/EO/903) ("Notification"). Applicant believes that such a Petition is appropriate under the conditions set forth in 37 C.F.R. 1.181(a). For the reasons stated herein, Applicant respectfully submits that the Notification was clearly in error. Accordingly, reinstatement of the above application as a U.S. National Stage application is respectfully requested.

**Statement of Facts/Background**

On September 24, 2001, Applicant filed the above application in the U.S. Designated/Elected Office. The contents of the filing included:

Express Mail No.:  
EV022027699US

- (1) Transmittal Form PCT/DO/EO/1390 indicating that the application is a national stage filing (**Tab 1**);
- (2) A copy of the PCT Request filed in the corresponding PCT application;
- (3) A copy of the PCT Cover Sheet filed in the corresponding PCT application;
- (4) A copy of the International Preliminary Examination Report issued for the corresponding PCT application;
- (5) A copy of the International Search Report issued for the corresponding PCT application;
- (6) A Information Disclosure Statement under 37 CFR 1.97 and 1.98;
- (7) A first Preliminary Amendment; and
- (8) An oath or declaration of the inventor(s) submitted in accordance with 37 USC 371(c)(3) (**Tab 2**)

On October 30, 2001 a Notice of Acceptance of Application Under 35 U.S.C. 371 and 37 C.F.R. 1.494 or 1.495 was mailed to Applicant, along with a Filing Receipt (both of which are enclosed at **Tab 3**). The Notice of Acceptance explicitly stated that International Application PCT/EP00/01444 had met the requirements of 35 U.S.C. 371 and was accepted for national patentability examination. The Filing Receipt indicated that the national phase application was a 371 of PCT/EP00/01444 under the "Domestic priority data as claimed by applicant".

Subsequently, on May 2, 2002, an Office Action on the merits was mailed to Applicant. Applicant timely filed a response to the Office Action on July 30, 2002. In the response, Applicant amended page 1 of the specification to properly reflect the lineage of the present U.S. application in relation to PCT International Application No. PCT/EP00/01444. Applicant also concurrently filed a Petition to Accept an Unintentionally Delayed Priority Claim Under 37 C.F.R. 1.78(a)(3).

On September 25, 2002, the PCT Legal Office issued the Notification vacating the Notification of Acceptance of Application under 35 U.S.C. § 371 and 37 CFR 1.494 or 1.495 (Form PCT/DO/EO/903) and ordered the application be processed as an application under 35 U.S.C. 111(a) and not as a U.S. national stage application. The PCT Legal Office reached this decision because, in its opinion, Applicant's First Preliminary Amendment filed concurrently with request for entry into the national phase contained the header "Preliminary Amendment Under 35 U.S.C. 111". The PCT Legal Office alleged that this statement gave rise to a level of ambiguity as to whether an application under 111(a) or a national stage application was intended to be filed by Applicant. Citing 37 C.F.R. 1.495(g) and MPEP 1893.03(a) in support of its position, the PCT Legal Office indicated that, in the event that an ambiguity is present, the application must be treated as a 111(a) application.

**Statement/Point for Review by Commissioner**

**The vacation of the above application as a national stage application under 35 U.S.C. 371 by the PCT Legal Office was in error**

For the reasons set forth below, Applicant respectfully submits that the PCT Legal Office's Notification ordering the application be processed as a 111(a) application was clearly in error. Applicant's position is based largely upon the standard provided by 37 C.F.R. 1.495(g) and MPEP 1893.03(a) for evaluating whether a national phase application or an application under 35 U.S.C. 111 is intended to be filed. Accordingly, Applicant respectfully requests that the decision of the PCT Legal Office set forth in the Notification be set aside and that the application be treated as a national stage application as correctly determined by the Patent Office.

In support of its argument, the PCT Legal Office cites 37 C.F.R. 1.495(g) and MPEP 1893.03(a) for the position that an ambiguity as to whether an application is to be filed as a national stage or a 111(a) application is to be resolved in favor of a 111(a) application. Applicant does not dispute

such a position. Applicant instead submits that no such ambiguity exists. Moreover, Applicant submits that the PCT Legal Office has arrived at its decision without a thorough analysis to the C.F.R. and MPEP provisions that it has cited. When evaluating the arguments of the PCT Legal Office properly in view of the above C.F.R. and MPEP provisions taken in their entirety, it is clear that the position of the PCT Legal Office is without merit.

37 C.F.R. 1.495(g) states:

“The documents and fees submitted under paragraphs (b) and (c) of this section must, except for a copy of the international publication or translation of the international application that is identified as provided in § 1.417, be clearly identified as a submission to enter the national stage under under 35 U.S.C. 371. Otherwise, the submission will be considered as being made under 35 U.S.C. 111(a)”

37 C.F.R. 1.495(b) and (c) states as follows:

“To avoid abandonment of the application the applicant shall furnish to the United States Patent and Trademark Office not later than the expiration of 30 months from the priority date:

- (1) **A copy of the international application**, unless it has been previously communicated by the International Bureau or unless it was originally filed in the United States Patent and Trademark Office; and
- (2) **The basic national fee (see § 1.492(a))**. The 30-month time limit may not be extended.”

(emphasis added)

37 C.F.R. 1.495 (c) states:

“If applicant complies with paragraph (b) of this section before expiration of 30 months from the priority date but omits:

- (1) A translation of the international application, as filed, into the English language, if it was originally filed in another language (35 U.S.C. 371(c)(2)) and/or

(2) ***The oath or declaration of the inventor*** (35 U.S.C. 371(c)(4); see § 1.497), and a declaration of inventorship in compliance with § 1.497 has not been previously submitted in the international application under PCT Rule 4.17(iv) within the time limits provided for in PCT Rule 26ter.1. applicant will be so notified and given a period of time within which to file the translation and/or oath or declaration in order to prevent abandonment of the application. The payment of the processing fee set forth in § 1.492(f) is required for acceptance of an English translation later than the expiration of 30 months after the priority date. The payment of the surcharge set forth in § 1.492(e) is required for acceptance of the oath or declaration of the inventor later than the expiration of 30 months after the priority date. A "Sequence Listing" need not be translated if the "Sequence Listing" complies with PCT Rule 12.1(d) and the description complies with PCT Rule 5.2(b)."

(emphasis added).

It is clear that Applicant has provided the items referenced in 37 C.F.R. 1.495(g) and that those items were clearly marked as intended for national stage entry. Such documents include:

- (a) a copy of the International Application;
- (b) the basic national fee under § 1.492(a); and
- (c) an Oath or Declaration under 35 U.S.C. 371(c)(4).

With the exception of a copy of the International Application, such items were filed concurrently with the request to enter the national phase and were listed on Transmittal Form PCT/DO/EO/1390 (see **Tab 1**)<sup>1</sup>. Receipt of these items was acknowledged by the Patent Office in the Notification of Acceptance of Application. Accordingly, in view of 37 C.F.R. 1.495(g), which was cited by the PCT Legal Office in its Notification, Applicant respectfully submits that it unquestionably intended the application to enter the national stage as opposed to a 111(a) filing.

The PCT Legal Office also cites MPEP 1893.03(a), pages 1800-114 in support of its position. Applicant respectfully submits that a more thorough

---

<sup>1</sup> A copy of the International Application was transmitted by the International Bureau to the Patent Office. Acknowledgement of receipt of the International Application was indicated by the Notification of Acceptance of Application issued by the Patent Office

examination of this passage reveals that the present application was clearly intended for national stage entry.

MPEP 1893.03(a) lists three key factors in evaluating whether an application is to be considered as filed under 35 U.S.C. 371. Such factors are:

- (A) ***The file face indication of a filing under 35 U.S.C. 371;***
- (B) ***The Form PCT/DO/EO/903*** indicating acceptance of the application as a national stage filing under 35 U.S.C. 371; and ,
- (C) ***Applicant's statement (or the equivalent) in the originally filed application papers that the application is a national stage filing under 35 U.S.C. 371. Applicants who use transmittal Form PCT/DO/EO/1390 will satisfy the requirement for such a statement since the form includes an indication that the application is a national stage filing under 35 U.S.C. 371.***

(emphasis added)

With respect to factor (A), the filing of Transmittal Form PCT/DO/EO/1390 (see **Tab 1**) by Applicant fulfills its requirement. In particular, the first line of Form PCT/DO/EO/1390 states:

"Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 U.S.C. 371"

With respect to factor (B), the Patent Office issued a Form PCT/DO/EO/903 indicating acceptance of the application as a national phase filing. See **Tab 3**. Accordingly, this factor is met.

With respect to factor (C), Applicant has provided a statement that the application is a national stage filing under 35 U.S.C. 371 by virtue of the submission of Form PCT/DO/EO/1390. See **Tab 1**. Factor (C) indicates that "Applicants who use transmittal form PCT/DO/EO/1390 will satisfy the requirement for such a statement..." (MPEP 1893.03(a)). Therefore, this factor is believed to be satisfied.

In addition to the above, MPEP 1893.03(a) further states:



“... In accordance with the notice at 1077 O.G. 13 (14 April 1987), if the applicant files a U.S. national application and clearly identifies in the accompanying oath or declaration the specification to which it is directed by referring to a particular international application by PCT Application Number and International Filing Date and that he or she is executing the declaration as, and seeking a U.S. Patent as, the inventor of the invention described in the identified international application, then the application will be accepted as filed under 35 U.S.C. 371. ...”

(emphasis added)

Applicant refers the Commissioner to **Tab 2** which is a copy of the inventor's Declaration filed concurrently with the application. The Declaration clearly indicates that the reference application is PCT International Application No. PCT/EP00/01444 filed 23 February 2000. Therefore, in accordance with the passage of MPEP 1893.03(a) cited above, the present application is to accepted as filed under 35 U.S.C. 371.

### **Conclusion/Action Requested**

When properly analyzed in light of the appropriate legal standards, Applicant respectfully submits that the present application was unquestionably intended for national phase filing under 35 U.S.C. 371. In view of such an analysis, a single statement in a Preliminary Amendment referring to 35 U.S.C. 111 cannot be construed as giving rise to an ambiguity as to the intention of the filing<sup>2</sup>. The evidence of record overwhelmingly indicates that Applicant intended the application be filed as a national stage application.

In view of the above, Applicant respectfully requests that the Commissioner reverse the decision of the PCT Legal Office set forth in the Notification, and that the Application be properly afforded its initial and correct status as a national stage application.

In accordance with 37 C.F.R. 1.181(f), this Petition is considered to be timely filed because it is filed within two months from the mailing of the Notification. Additionally, the Commissioner is authorized to charge Deposit Account No.07-1392 for any fee that may be due so as to fulfill the requirement of 37 C.F.R. 1.181(d).

It is encouraged that Applicant's undersigned representative be contacted at (919) 483-9616 in the event that there are any questions or concerns pertaining to the above.

Respectfully submitted,

Date: November 8, 2002



Robert J. Smith  
Reg. No. 40,820  
Attorney for Applicants

GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
PO Box 13398  
Research Triangle Park, NC 27709-3398  
Direct Phone (919)483-9616  
Facsimile (919)483-7988



23347

PATENT TRADEMARK OFFICE

---

<sup>2</sup> Applicant submits that this statement in the Preliminary Amendment was an inadvertent typographical error and made without deceptive intent.

**Associate Power Of Attorney Or Agent (37 CFR 1.34)  
(For Representation Related To A Patent Application)**

Docket No.  
**PG3654USw**

In Re Application Of:  
**ANDERSON, et. al.**

Serial No.  
**09/937,232**

Filing Date  
**09/24/2001**

Examiner  
**CARTAGENA**

Group Art Unit  
**3754**

Invention:  
**VALVE**

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Please recognize the following as ☒ Associate Attorney ☐ Associate Agent in this application.

Name: **Robert J. Smith**

Reg. No.: **40,820**


Address: **GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
PO Box 13398  
Research Triangle Park, NC 27709**



**23347**

PATENT TRADEMARK OFFICE

Tel. No. **919-483-9616** / Facsimile No. : **919-483-7988**

  
Signature of Principal Attorney or Agent of Record

**Christopher P. Rogers  
Reg. No.: 36,334  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
PO Box 13398  
Research Triangle Park, NC 27709**

Registration Number & Address of Principal Attorney or Agent of Record

Dated:

**30 July 2002**

I certify that this document is being deposited on  
**7-30-02** with the U.S. Postal Service as first  
class mail under 37 C.F.R. 1.8 and is addressed to the  
Assistant Commissioner for Patents, Washington, D.C.  
20231.



Signature of Person Mailing Correspondence

**Ban Younan**

Typed or Printed Name of Person Mailing Correspondence

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

PG36 USW

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

INTERNATIONAL APPLICATION  
PCT/EP00/01444INTERNATIONAL FILING DATE  
23 February 2000PRIORITY DATE CLAIMED  
24 March 1999TITLE OF INVENTION  
VALVE

APPLICANT(S) FOR DO/EO/US

Gregor John McLennan; ANDERSON; Marck Andrew HAILEY; David Joseph RUSSELL; James William GODFREY

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). *Anderson, Hailey, Russell, Godfrey.*
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

## Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Copy of PCT Request  
Copy of PCT Cover Sheet

RECEIVED

FEB 24 2003

TECHNOLOGY CENTER R3700

PCT/EP00/01444

PG3654USW

24. The following fees are submitted:

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1000.00
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	30 - 20 =	10	x \$18.00
Independent claims	1 - 3 =	0	x \$80.00

Multiple Dependent Claims (check if applicable) ☐**TOTAL OF ABOVE CALCULATIONS =**

- ☐ Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.

**SUBTOTAL =**

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

**TOTAL NATIONAL FEE =**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

**TOTAL FEES ENCLOSED =**

Amount to be refunded	\$
charged	\$

- a. ☐ A check in the amount of \_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 07-1392 in the amount of 1040.<sup>00</sup> to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 07-1392. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

David J. Levy  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709  
Telephone: 919-483-2370  
Fax: 919-483-7988



23347

PATENT TRADEMARK OFFICE

SIGNATURE

Christopher P. Rogers

NAME

36,334

REGISTRATION NUMBER

September 24, 2001

DATE

CALCULATIONS PTO USE ONLY

RECEIVED

FEB 24 2003

TECHNOLOGY CENTER R3700

\$860.00

\$0.00

\$180.00

\$0.00

\$0.00

\$1,040.00

\$0.00



\$1,040.00

\$0.00

\$1,040.00

\$0.00

\$1,040.00

PCT/EP00/01444		ATTORNEY SOCKET NUMBER PG3654USW																																																					
24. The following fees are submitted: <b>BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :</b> <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1000.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00 <div style="text-align: right;"><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></div>		<b>CALCULATIONS PTO USE ONLY</b>  <div style="border: 1px solid black; height: 100px; width: 100%;"></div>																																																					
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).		\$860.00																																																					
<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:20%;">CLAIMS</th> <th style="width:20%;">NUMBER FILED</th> <th style="width:20%;">NUMBER EXTRA</th> <th style="width:20%;">RATE</th> </tr> <tr> <td>Total claims</td> <td>30 - 20 =</td> <td>10</td> <td>x \$18.00</td> </tr> <tr> <td>Independent claims</td> <td>1 - 3 =</td> <td>0</td> <td>x \$80.00</td> </tr> <tr> <td colspan="3">Multiple Dependent Claims (check if applicable) <input type="checkbox"/></td> <td>\$0.00</td> </tr> <tr> <td colspan="3" style="text-align: right;"><b>TOTAL OF ABOVE CALCULATIONS =</b></td> <td>\$1,040.00</td> </tr> <tr> <td colspan="3"> <input type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.         </td> <td>\$0.00</td> </tr> <tr> <td colspan="3" style="text-align: right;"><b>SUBTOTAL =</b></td> <td>\$1,040.00</td> </tr> <tr> <td colspan="3">         Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).       </td> <td style="text-align: center;">\$0.00</td> </tr> <tr> <td colspan="3" style="text-align: right;"><b>TOTAL NATIONAL FEE =</b></td> <td>\$1,040.00</td> </tr> <tr> <td colspan="3">         Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable) <input type="checkbox"/> </td> <td style="text-align: center;">\$0.00</td> </tr> <tr> <td colspan="3" style="text-align: right;"><b>TOTAL FEES ENCLOSED =</b></td> <td>\$1,040.00</td> </tr> <tr> <td colspan="2"></td> <td style="text-align: center;">Amount to be refunded</td> <td style="text-align: center;">\$</td> </tr> <tr> <td colspan="2"></td> <td style="text-align: center;">charged</td> <td style="text-align: center;">\$</td> </tr> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total claims	30 - 20 =	10	x \$18.00	Independent claims	1 - 3 =	0	x \$80.00	Multiple Dependent Claims (check if applicable) <input type="checkbox"/>			\$0.00	<b>TOTAL OF ABOVE CALCULATIONS =</b>			\$1,040.00	<input type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.			\$0.00	<b>SUBTOTAL =</b>			\$1,040.00	Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).			\$0.00	<b>TOTAL NATIONAL FEE =</b>			\$1,040.00	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable) <input type="checkbox"/>			\$0.00	<b>TOTAL FEES ENCLOSED =</b>			\$1,040.00			Amount to be refunded	\$			charged	\$	a. <input type="checkbox"/> A check in the amount of _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>07-1392</u> in the amount of <u>1040<sup>00</sup></u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>07-1392</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																																																				
Total claims	30 - 20 =	10	x \$18.00																																																				
Independent claims	1 - 3 =	0	x \$80.00																																																				
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>			\$0.00																																																				
<b>TOTAL OF ABOVE CALCULATIONS =</b>			\$1,040.00																																																				
<input type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.			\$0.00																																																				
<b>SUBTOTAL =</b>			\$1,040.00																																																				
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).			\$0.00																																																				
<b>TOTAL NATIONAL FEE =</b>			\$1,040.00																																																				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable) <input type="checkbox"/>			\$0.00																																																				
<b>TOTAL FEES ENCLOSED =</b>			\$1,040.00																																																				
		Amount to be refunded	\$																																																				
		charged	\$																																																				
<b>NOTE:</b> Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.																																																							
SEND ALL CORRESPONDENCE TO:																																																							
David J. Levy GlaxoSmithKline Corporate Intellectual Property Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 Telephone: 919-483-2370 Fax: 919-483-7988		 <b>23347</b> PATENT TRADEMARK OFFICE																																																					
		 SIGNATURE <b>Christopher P. Rogers</b> NAME <u>36,334</u> REGISTRATION NUMBER <b>September 24, 2001</b> DATE																																																					

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

ANDERSON, et al.

Serial No.:

09/397,232

Filed:

09/24/2001

For: VALVE

Group Art Unit: 3754

Examiner: CARTAGENA, Melvin

Commissioner for Patents  
Washington, D.C. 20231



RECEIVED

AUG - 8 2002

TECHNOLOGY CENTER R3700

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed: AA, AB, BA

☐ Copies of the references were submitted in parent application Serial No. \_\_\_\_\_ (37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☒ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

(1) a final action under § 1.113 or

(2) a notice of allowance under § 1.311,

whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Attorney of Record: Robert J. Smith  
Registration No. 40,820

GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-9616  
Facsimile: (919) 483-7988



23347

PATENT TRADEMARK OFFICE

**CERTIFICATE OF MAILING (37 CFR 1.8)**

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents, Washington, D.C. 20231.

Date: 7-30-02

  
Bar Younan




**COMBINED DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION WITH POWER OF ATTORNEY**ATTORNEY'S DOCKET  
PG3654USWFirst Names Inventor:  
Gregor John McLennan  
ANDERSON**Complete if known:**  
App No.:

Filing Date

Group Art Unit:

( ) Declaration submitted with initial filing or

( ) Declaration submitted after initial filing (surcharge required 37CFR1.16(e))



As below named inventor. I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**VALVE**

the specification of which (check only one item below):

[ ] is attached hereto.

OR

[ x ] was filed on **23 February 2000** as United States application Serial No. \_\_\_\_\_ or PCT InternationalApplication Number **PCT/EP00/01444** filed and was amended on (MM/DD/YYYY) \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under 35, U.S.C. §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed:

**PRIOR FOREIGN AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:**


Prior Foreign Application Number (s)	Country	Foreign Filing Date (MM/DD/YYYY)	PRIORITY CLAIMED
1 9906640.9	GB	March 24, 1999	X
2.			
3.			
4.			
5.			

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below:


Application No.	Filing Date (MM/DD/YYYY)	
1.		
2.		
3.		
4.		


Express Mail No.:  
EV022027699US

## DECLARATION FOR "371" APPLICATION

<b>COMBINED DECLARATION FOR UTILITY or DESIGN PATENT APPLICATION WITH POWER OF ATTORNEY</b>				ATTORNEY'S DOCKET NUMBER <b>PG3654USW</b>																
Continued																				
I hereby claim the benefit under 35, U.S.C. §120 of any United States application or §365(c) of any PCT international application designating the United States of America that is listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:																				
<b>PRIOR U.S. PARENT APPLICATION or PCT PARENT APPLICATION</b>																				
U.S. Parent Application or PCT Parent Number		Parent Filing Date (MM/DD/YYYY)		STATUS (Check one)																
				<input type="checkbox"/> PATENTED <input type="checkbox"/> PENDING <input type="checkbox"/> ABANDONED																
<b>POWER OF ATTORNEY:</b> As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the U.S. Patent and Trademark Office connected therewith. (List name and registration number)																				
<table style="width: 100%; border: none;"> <tr> <td style="width: 25%;">David J. Levy      Reg. No. 27,655</td> <td style="width: 25%;">James P. Riek      Reg. No. 39,009</td> <td style="width: 25%;">Bonnie L. Deppenbrock      Reg. No. 28,209</td> </tr> <tr> <td>Charles E. Dadswell      Reg. No. 35,851</td> <td>Virginia C. Bennett      Reg. No. 37,092</td> <td>John L. Lemanowicz      Reg. No. 37,380</td> </tr> <tr> <td>Karen L. Prus      Reg. No. 39,337</td> <td>Frank P. Grassler      Reg. No. 31,164</td> <td>Amy H. Fix      Reg. No. 42,616</td> </tr> <tr> <td>Robert H. Brink      Reg. No. 36,094</td> <td>Christopher P. Rogers      Reg. No. 36,334</td> <td></td> </tr> <tr> <td>Elizabeth Selby      Reg. No. 38,298</td> <td>Lorie Ann Morgan      Reg. No. 38,181</td> <td></td> </tr> </table>						David J. Levy      Reg. No. 27,655	James P. Riek      Reg. No. 39,009	Bonnie L. Deppenbrock      Reg. No. 28,209	Charles E. Dadswell      Reg. No. 35,851	Virginia C. Bennett      Reg. No. 37,092	John L. Lemanowicz      Reg. No. 37,380	Karen L. Prus      Reg. No. 39,337	Frank P. Grassler      Reg. No. 31,164	Amy H. Fix      Reg. No. 42,616	Robert H. Brink      Reg. No. 36,094	Christopher P. Rogers      Reg. No. 36,334		Elizabeth Selby      Reg. No. 38,298	Lorie Ann Morgan      Reg. No. 38,181	
David J. Levy      Reg. No. 27,655	James P. Riek      Reg. No. 39,009	Bonnie L. Deppenbrock      Reg. No. 28,209																		
Charles E. Dadswell      Reg. No. 35,851	Virginia C. Bennett      Reg. No. 37,092	John L. Lemanowicz      Reg. No. 37,380																		
Karen L. Prus      Reg. No. 39,337	Frank P. Grassler      Reg. No. 31,164	Amy H. Fix      Reg. No. 42,616																		
Robert H. Brink      Reg. No. 36,094	Christopher P. Rogers      Reg. No. 36,334																			
Elizabeth Selby      Reg. No. 38,298	Lorie Ann Morgan      Reg. No. 38,181																			
Send Correspondence to: David J. Levy, Patent Counsel Corporate Intellectual Property Department GlaxoSmithKline Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709				 <b>23347</b> PATENT TRADEMARK OFFICE																
				Direct Telephone Calls to:  Christopher P. ROGERS 919-483-1240																
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.																				
2  0  1	FULL NAME OF INVENTOR	FAMILY NAME <b>ANDERSON</b>	FIRST GIVEN NAME <b>Gregor</b>	SECOND GIVEN NAME/INITIAL <b>John, McLennan</b>																
	INVENTOR'S SIGNATURE	Signature <i>AKELAN ANDERSON</i>			Date: X <i>30 AUG 2001</i>															
	RESIDENCE & CITIZENSHIP	CITY <b>Ware</b>	STATE OR FOREIGN COUNTRY <b>GB</b>	COUNTRY OF CITIZENSHIP <b>GB</b>																
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>GlaxoSmithKline Five Moore Drive, PO Box 13398</b>			STATE & ZIP CODE/COUNTRY <b>North Carolina 27709, US</b>															
2  0  2	FULL NAME OF INVENTOR	FAMILY NAME <b>HAILEY</b>	FIRST GIVEN NAME <b>Mark</b>	SECOND GIVEN NAME/INITIAL <b>Andrew</b>																
	INVENTOR'S SIGNATURE	Signature <i>M Hailey</i>			Date: X <i>30 Aug 01</i>															
	RESIDENCE & CITIZENSHIP	CITY <b>Ware</b>	STATE OR FOREIGN COUNTRY <b>GB</b>	COUNTRY OF CITIZENSHIP <b>GB</b>																
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>GlaxoSmithKline Five Moore Drive, POBox 13398</b>			STATE & ZIP CODE/COUNTRY <b>North Carolina 27709, US</b>															
2  0  3	FULL NAME OF INVENTOR	FAMILY NAME <b>RUSSELL</b>	FIRST GIVEN NAME <b>David</b>	SECOND GIVEN NAME/INITIAL <b>Joseph</b>																
	INVENTOR'S SIGNATURE	Signature <i>DRussell</i>			Date: X <i>10 Sep 01</i>															
	RESIDENCE & CITIZENSHIP	CITY <b>Ware</b>	STATE OR FOREIGN COUNTRY <b>GB</b>	COUNTRY OF CITIZENSHIP <b>GB</b>																
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>GlaxoSmithKline Five Moore Drive, POBox 13398</b>			STATE & ZIP CODE/COUNTRY <b>North Carolina 27709, US</b>															

## DECLARATION FOR "371" APPLICATION

2	FULL NAME OF INVENTOR	FAMILY NAME <b>GODFREY</b>	FIRST GIVEN NAME <b>James</b>	SECOND GIVEN NAME/INITIAL <b>William</b>
0	INVENTOR'S SIGNATURE	Signature 	Date: <b>X 12 Sept 01</b>	
4	RESIDENCE & CITIZENSHIP	CITY <b>Ware</b>	STATE OR FOREIGN COUNTRY <b>GB</b>	COUNTRY OF CITIZENSHIP <b>GB</b>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <b>GlaxoSmithKline Five Moore Drive, POBox 13398</b>	CITY <b>Durham</b>	STATE & ZIP CODE/COUNTRY <b>North Carolina 27709, US</b>



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/937,232	09/24/2001	3754	1040	PG3654USW	3	30	1

CONFIRMATION NO. 6565

23347  
DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY  
GLAXOSMITHKLINE  
FIVE MOORE DR.  
PO BOX 13398  
DURHAM, NC 27709-3398

## FILING RECEIPT



\*OC000000006974719\*

Date Mailed: 10/30/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Gregor John McLennan Anderson, Durham, NC;  
Mark Andrew Hailey, Durham, NC;  
David Joseph Russell, Durham, NC;  
James William Godfrey, Durham, NC;

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/EP00/01444 02/23/2000

## Foreign Applications

UNITED KINGDOM 9906640.9 03/24/1999

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No


## Title

Valve

## Preliminary Class

Express Mail No.:  
EV022027699US

251



**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

NOV 08 2002

☒ Commissioner For Patents, Box PCT, United States Patent and Trademark Office, Washington, D.C. 20231, www.uspto.gov

U.S. APPLICATION NUMBER NO.

FIRST NAMED APPLICANT

ATTY. DOCKET NO.

09/937,232

Gregor John McLennan Anderson

PG3654USW

INTERNATIONAL APPLICATION NO.

PCT/EP00/01444

I.A. FILING DATE

PRIORITY DATE

02/23/2000

03/24/1999

23347

DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY  
GLAXOSMITHKLINE  
FIVE MOORE DR.  
PO BOX 13398  
DURHAM, NC 27709-3398

CONFIRMATION NO. 6565

371 ACCEPTANCE LETTER



\*OC00000006974720\*

Date Mailed: 10/30/2001

### NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.494 OR 1.495

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as an Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.

The United States Application Number assigned to the application is shown above and the relevant dates are:

09/24/2001

DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and  
(c)(4) REQUIREMENTS

09/24/2001

DATE OF RECEIPT OF ALL 35 U.S.C.  
REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. **THE DATE APPEARING ON THE FILING RECEIPT AS THE " FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C. 371 REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE.** *The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363).* Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

The following items have been received:

- U.S. Basic National Fee
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

---

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

---

TAMALA D HOLLAND

Telephone: (703) 305-5483

PART 1 - ATTORNEY/APPLICANT COPY